Kornimate/medical-research-clean huggingface dataset:
registry and fluid banking of pancreatic cystic lesions

Conditions: Pancreatic Cysts

Summary: the purpose of this study is to follow patients, who have small mucinous cysts in the pancreas, prospectively over a 5-year period.

the patients will present to our endoscopy unit for eus-fna to work up pancreatic cystic lesion(s). at that time, we will recruit them to be in the patient registry and tissue repository. their enrollment in the patient registry will allow us to contact them annually for survey purposes. their enrollment in the tissue repository will allow us to store left-over pancreatic cyst fluid that was already aspirated for analysis (as part of the standard-of-care workup for pancreatic cysts).

Eligibility criteria:
inclusion criteria: * consented patients between age 18 to 85 who are referred for eus evaluation of pancreatic cysts. exclusion criteria: * patient unable to give informed consent * age\ 85, patients with clinically suspected pseudocysts.
safety of nnc 0123-0000-0338 in healthy subjects

Conditions: Diabetes; Healthy

Summary: this trial is conducted in europe. the aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body), and the pharmacodynamics (the effect of the investigated drug on the body) of nnc 0123-0000-0338 as tablets in healthy subjects.


Eligibility criteria:
inclusion criteria: * male subject * body mass index (bmi) between 18 and 28 kg/m\^2 (both inclusive) exclusion criteria: * known or suspected hypersensitivity to trial products or related products * presence of clinically significant acute gastrointestinal symptoms (e.g. nausea, vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the trial physician * presence of any medical condition that may confound the results of the trial or pose an unacceptable risk to the subject by administering the trial product, as judged by the trial physician
long-term effects of covid-19 in adolescents

Conditions: Covid19

Summary: the overarching objective for this prospective cohort study of covid-19 in adolescents is to study the long-term effects, with particular emphasis on post-infectious chronic fatigue. a total of 500 individuals with a sars-cov-2 positive test will be enrolled in the acute phase of covid-19 and followed for 6 months. a total of 100 individuals with sars-cov-2 negative test will be included during the same time period as a control group. investigations include autonomic, pulmonary and cognitive assessement; a questionnaire charting symptoms, emotionality, personality, loneliness, life events and demographics; and extensive biobanking including genetic markers, viable pbmc, urine, feces and hair. a subgroup of 40 sars-cov-2 positive and 20 sars-cov-2 negative individuals will also undergo detailed cardiological examination by echocardiography. primary endpoints are fatigue at 6 months as assessed by the chalder fatigue scale and post-covid-19 syndrome cases at 6 months according to the who definition


Eligibility criteria:
inclusion criteria: * positive sars-cov-2 test/negative sars-cov-2 test * age 12 - 25 years * living in the counties of oslo or viken, norway * \< 28 days since onset of first symptom exclusion criteria: * hospitalised due to covid-19 * pregnancy * lack of consent
in vivo lung perfusion (ivlp) for colorectal cancer metastatic to lung

Conditions: Lung Metastases; Colorectal Cancer Metastatic; Colorectal Cancer

Summary: this study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy. this technique is called in vivo lung perfusion (ivlp). at the university health network, this ivlp technique has been used recently in a phase i study in patients with sarcoma, and we are now expanding on that experience to include patients with colorectal metastases. the purpose of this study is to test the safety of the ivlp technique and find the dose that seems right in humans. participants are given oxaliplatin into one lung via ivlp and are watched very closely to see what side effects they have and to make sure the side effects are not severe. if the side effects are not severe, then more participants are asked to join the study and are given a higher dose of oxaliplatin. participants joining the study later on will get higher doses of oxaliplatin than participants who join earlier. this will continue until a dose is found that causes severe but temporary side effects. doses higher than that will not be given. the other lung will not be infused with anything, so that we can limit unforeseen toxicity to a single lung and see if one lung does better than the other.


Eligibility criteria:
inclusion criteria: 1. diagnosis of colorectal carcinoma 2. presence of bilateral pulmonary metastases 3. 3 or more lung lesions in total 4. age 70 years or less 5. ecog 0-2 6. absence of extra-pulmonary disease, except liver metastases suitable to curative treatment. exclusion criteria: 1. patient has previously received more than 1000 mg of oxaliplatin 2. left ventricular ejection fraction \<50% 3. history of significant pulmonary disease or pneumonitis 4. pregnant or lactating females 5. age 71 or older, or less than 18 years 6. inability to understand the informed consent process 7. hypersenstivity to oxaliplatin 8. patients with heparin-induced thrombocytopenia (hit) 9. patients who cannot receive cefazolin or methylprednisolone due to allergy or another reason can be included but will not receive the drug they cannot tolerate 10. current participation in another therapeutic clinical trial

Keywords: ivlp metastatic
a study to evaluate usability of subcutaneous auto-injector of ct-p47 in patients with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this is a phase 3 study to evaluate the usability of the ct-p47 auto-injector in patients with moderate to severe active rheumatoid arthritis.

ct-p47, containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that is being developed as a similar biological medicinal product to roactemra/actemra. the purpose of this study is to evaluate the usability of the ct-p47 auto-injector in patients with moderate to severe rheumatoid arthritis when co-administered with methotrexate.

Eligibility criteria:
inclusion criteria: * patient is male or female aged 18 to 70 years old, both inclusive. * patient must be able and willing to self-administer sc injections. * patient has had a diagnosis of ra according to the 2010 acr/eular classification criteria (aletaha et al., 2010) for at least 24 weeks prior to the first administration of the study drug (day 1). exclusion criteria: * patient who has previously received investigational or licensed product; targeted synthetic dmard(s) (e.g., tofacitinib, baricitinib) for the treatment of ra and/or an interleukin-6 (il-6) inhibitor for any purposes. * patient who has previously received more than 1 biologic agents approved for the treatment of ra. * patient who has allergies to any of the excipients of study drug or any other murine and human proteins, or patient with a hypersensitivity to immunoglobulin products.
the effects of helicobacter pylori eradication on proteinuria in patients with membranous nephropathy

Conditions: Nephrotic Syndrome; Glomerulonephritis; Membranous Nephropathy

Summary: membranous nephropathy (mn) may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). in this study, the presence of helicobacter pylori (h. pylori) antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of h. pylori infection and the effects of h. pylori eradication on proteinuria level in patients with mn will be investigated.

membranous nephropathy (mn) is a common cause of nephrotic syndrome in adults. it is thought to be mainly a primary or idiopathic form; however, it may also be secondary to many other diseases (e.g., infections, drugs, neoplasms and autoimmune diseases). in this study, the presence of helicobacter pylori antigen was investigated in renal tissue from needle biopsy samples, and the prevalence of h. pylori infection and the effects of h. pylori eradication on proteinuria level in patients with mn will be investigated.

Eligibility criteria:
inclusion criteria: * age between 18-70 years * nondiabetic patients * patients with primary glomerulonephritis * clinical diagnosis of membranous nephropathy, iga nephropathy or focal segmental glomerulosclerosis confirmed by biopsy * glomerular filtration rate \> 30 ml/min * patients who did not receive helicobacter pylori eradication therapy within the last three months before enrollment in study exclusion criteria: * patients with secondary glomerulonephritis * glomerular filtration rate \< 30 ml/min * patients who received helicobacter pylori eradication therapy within the last three months before enrollment in study * patients with a history of gastric surgery * patients without an informed consent

Keywords: nephrotic syndrome helicobacter pylori infection proteinuria membranous nephropathy
atrio-ventricular (av) delay optimization using echocardiography versus the sonr signal

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate an external device (sonr sensor) that is capable of detecting sounds created by the heart (sonr signal). based on the sounds created by the heart and recorded by the sonr sensor, optimal timing settings for the cardiac resynchronization therapy defibrillator (crt-d) device may be determined. the investigators will then compare the timing settings suggested by sonr to the settings suggested from the echocardiogram. the objective of this study is to determine if differences exist between these different methods of timing the contractions of the top and bottom chambers of the heart and if the sonr signal is able to produce results similar to those of an echocardiogram.


Eligibility criteria:
inclusion criteria: * implanted with any current food and drug administration (fda) approved crt- d device and leads for 30 days or patients indicated for av optimization * ≥18 years of age * ability and willingness to provide written informed consent and hipaa authorization exclusion criteria: * chronic atrial fibrillation * heart failure decompensation event within two weeks of enrollment * hypertrophic obstructive cardiomyopathy * patient currently enrolled in another ongoing clinical trial * pregnancy * less than 18 years of age * inability or unwillingness to provide written informed consent and hipaa authorization
intrathecal dexmedetomidine vs midazolame

Conditions: Postoperative Pain

Summary: prospective randomized controlled clinical trial to compare intrathecal dexmedetomidine versus midazolame in orthopedic cancer surgeries

comparison of intrathecal dexmedetomidine plus bupivacaine vs intrathecal midazolam plus bupivacaine on duration of sensory and motor blockade and hemodynamic parameters of patients

Eligibility criteria:
inclusion criteria: * patients undergoing lower limb orthopedic cancer surgery. * asa i, ii, iii. * age 20 to 70 year * healthy volunteers exclusion criteria: * age less than 20 and older than 70. * asa iv, v. * patients' refusal. * patients with coagulopathy. * patients with severe valvular stenosis * patients with infection at site of injection
antiproteinuric effect of imidapril versus ramipril in type 2 diabetic and hypertensive patients with microalbuminuria

Conditions: Hypertension; Type 2 Diabetes Mellitus; Microalbuminuria

Summary: numerous clinical and experimental data show that the elective treatment of diabetic nephropathy should be based on drugs that inhibit the renin-angiotensin system (ras). albuminuria is a marker of risk not only renal but also cardiovascular and diabetic patients with concomitant non-diabetic nephropathy, on the other hand, drugs blocking the renin-angiotensin system available so far, namely ace inhibitors and angiotensin antagonists ii have proven effective in reducing proteinuria in power even if different therapeutic drug to drug. ace inhibitors are one of the most known and used treatment options for blocking the renin-angiotensin system in patients with microalbuminuria. drugs such as enalapril, lisinopril and ramipril are standard therapy in diabetic patients with micro or macroalbuminuria. however, it is still unclear whether their efficacy is, from this point of view, the same or varies from drug to drug. this is particularly true in the diabetic microalbuminuria, a condition in which there is sufficient documentation to prove that ramipril is effective. the main objective of this study was to assess the magnitude and trend of the time and to the antiproteinuric effect of antihypertensive 10-20mg/die imidapril versus ramipril 5-10 mg / day in hypertensive patients with type 2 diabetes and microalbuminuria.


Eligibility criteria:
inclusion criteria: * blood pressure\> 130/80 ≤ 170/100 mmhg at the end of the period of wash-out * type 2 diabetes mellitus well controlled by medication and / or compliance with diet (hba1c \<7%) * microalbuminuria in the upper range of normal (\> 150 \<300 mg/24 h) exclusion criteria: * pregnancy, lactation or women of childbearing age. * inability to stop treatment in place for a few days during the wash-out. * sitting diastolic blood pressure\> 100 mmhg or systolic pressure\> 170 at the end of the wash-out. * history of hypertensive encephalopathy or cerebrovascular accident within 12 months prior. * secondary hypertension. * heart failure * acute myocardial infarction; angina pectoris * liver and kidney dysfunction * known hypersensitivity to ace inhibitors * all other physiological or pathological condition that the physician may affect the evaluation of the parameters under study or interfere with the proper conduct of the study.

Keywords: imidapril, ramipril, hypertension, type 2 diabetes mellitus, microalbuminuria
aerobic exercise in duchenne muscular dystrophy

Conditions: Duchenne Muscular Dystrophy

Summary: duchenne muscular dystrophy (dmd) is the most common neuromuscular disease in childhood with an estimate incidence of 1 in 3500 to 5000 male births. the effect of aerobic training on muscle architectural properties and motor functions such as muscle activation is not clear in dmd. the aim of this study is to investigate the effects of aerobic training on these parameters in children with dmd. twenty children with dmd included in the study will be divided into two groups as home program and home program+aerobic training with block randomization method. home program including stretching, respiratory, range of motion and mild resistance exercise with body weight will be asked to apply 3-5 days a week for 12 weeks, aerobic training will be performed 3 days a week for 12 weeks at 60% of their maximum hearth rate with 50 minutes total duration consisting of 10 min warm up and 10 min cool down period. muscle architectural properties, muscle strength, muscle activation and motor function will be assessed with ultrasonographic, hand-held myometry, surface emg and motor function measure, consecutively. assessments will be applied at pre-training and after 12 weeks of training.


Eligibility criteria:
inclusion criteria: * children had diagnosis of dmd confirmed by genetic analysis, * children had functional level of grade 1 and 2 according to vignos scale. exclusion criteria: * children had undergone any surgery or suffered injury of the lower limbs, * children had comorbid disease * children were applied regular aerobic training in last 6 months.

Keywords: duchenne muscular dystrophy aerobic training ultrasonography motor function
hepasphere interventional therapy using digital subtraction angiography（dsa）for breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to evaluate the safety and efficacy of hepasphere interventional therapy using digital subtraction angiography（dsa）for breast cancer.

by enrolling patients with breast cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of hepasphere interventional therapy using digital subtraction angiography（dsa）for breast cancer.

Eligibility criteria:
inclusion criteria: 1. age:18-80 2. karnofsky performance status \>60 3. diagnosis of breast cancer based on histology or the current accepted radiological measures. 4. classification tumor,nodes,metastasis-classification(tnm) stage: ⅱ,ⅲ,ⅳ 5. will receive interventional therapy 6. life expectancy: greater than 3 months 7. patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. ability to understand the study protocol and a willingness to sign a written informed consent document exclusion criteria: 1. patients with other primary tumor except breast cancer 2. history of coagulation disorders or anemia

Keywords: breast cancer hepasphere
genetic diagnosis and human growth hormone treatment in small for gestational age children with short stature

Conditions: Small for Gestational Age Infant; Silver-Russell Syndrome; Genetic Diseases, Inborn

Summary: this study is a multi-center, retrospective and non-interventional research. in this study, a total of 150 short children who were small for gestational age and had been treated with recombinant human growth hormone (rhgh) are selected for genetic testing. the aims of this study are to analyze the genetic etiology of sga children with short stature, and to compare the efficacy and safety of rhgh treatment in subjects with different etiologies.


Eligibility criteria:
inclusion criteria: 1. single birth, clinical diagnosis of sga; 2. rhgh treatment beginned before puberty (tanner stage i), regardless of gender; 3. before starting rhgh treatment, height was lower than -2 sds compared with normal children of the same age and sex; 4. all the subjects and their guardians signed the informed consent and the informed consent for genetic testing. exclusion criteria: 1. no efficacy and safety data were recorded after treatment with rhgh; 2. a history of blood transfusion within 3 months before the collection of the genetic blood samples, or a history of bone marrow transplantation between rhgh treatment and the enrollment in this study; 3. other conditions that the investigator considered unsuitable for inclusion in this study.
cadonilimab combined with s-1 or capecitabine as second-line treatment for advanced pancreatic cancer

Conditions: Pancreatic Neoplasms

Summary: this is a single arm, single cencer, phase ii clinical trial. this study aims to evaluate the efficacy and safety of cadonilimab combined with s-1 or capecitabine as a second-line treatment for advanced pancreatic cancer.


Eligibility criteria:
main inclusion criteria: * signed written informed consent * age 18-80, female or male * histopathologically confirmed pancreatic ductal adenocarcinoma * patients with locally advanced pancreatic cancer who have previously received standard first-line anti-tumor treatment (radiotherapy, chemotherapy, targeted or immunotherapy, etc.) * locally advanced pancreatic cancer is defined as follows: a. the tumor has no distant metastasis; b. pancreatic head/uncinate process: the tumor contacts the superior mesenteric artery \>180˚; c. pancreatic body and tail: the tumor contacts the superior mesenteric artery or celiac artery \>180˚; the tumor contacts the celiac artery and infiltrates the abdominal aorta; d. the tumor invades the jejunal branch of the superior mesenteric artery. portal vein-superior mesenteric vein cannot be safely reconstructed due to tumor invasion, vein occlusion, or involvement of a large range of jejunal branches of the superior mesenteric vein. * at least one measurable lesion (recist1.1) * ecog ps 0-1 * expected survival time\>3 months * adequate organ function main exclusion criteria: * malignant diseases other than pancreatic cancer diagnosed within 5 years before the first dose (excluding radically resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ) * currently participating in interventional clinical research treatment, or having received other research drugs or used research devices within 4 weeks before the first dose * active autoimmune disease * allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation * allergic to the active ingredients or excipients of this study drug, cadonilimab, s-1 or capecitabine * have not fully recovered from any toxicity and/or complications caused by the intervention before starting treatment * history of hiv * active hbv or hcv * pregnant or breastfeeding women * any severe or uncontrolled systemic disease * active pulmonary tuberculosis * people with mental disorders who are unable to cooperate with treatment * uncontrolled infection * the investigators assess that the subjects are unable to complete the entire trial process or are otherwise unsuitable for participating in this trial

Keywords: pd-1/ctla-4 bispecific antibody
comparison of levonorgestrel intrauterine system, copper t intrauterine device and oral contraceptives on life quality

Conditions: Contraceptive Methods Comparison

Summary: oral combined contraceptives(oc) have both progesterone and estrogen inside. levonorgestrel-releasing intrauterine device(lng_ius) has only progestagen. copper iud does not have any hormonal molecule inside. * hypothesis is oc has more systemic beneficial or side effects than lng_ius or copper iud. lng_ius has more local effects than copper iud. * study reflects the beneficial or side effects of estrogen+progestagen pills and only progestogen inside device.


Eligibility criteria:
inclusion criteria: * women who desire contraception exclusion criteria: * women with large fibroids,abnormal uterine bleeding including heavy menstrual bleeding or using any contraceptive pills during the previous 3 months were excluded from the study. other exclusion criteria were pelvic inflammatory disease, pregnancy, genital tumor or thromboembolic disease.

Keywords: lipid profile bleeding scores menstrual pattern beneficial side effects changes in a year period
sphenopalatine block versus botox in management of chronic migraine

Conditions: Sphenopalatine Block; BOTOX; Chronic Migraine

Summary: this trial compares the efficacy and safety of sphenopalatine ganglion block (spgb) and intramuscular botox injection in chronic migraine.

the international headache society's headache classification committee recognizes three broad categories of headaches: primary headaches, secondary headaches, and a third catchall category called "painful cranial neuropathies, other facial pain, and other headaches." migraines fall into the primary headache category. sphenopalatine ganglion (spg), or the pterygopalatine ganglion (ppg), is a large extracranial parasympathetic ganglion with multiple neural connections, including autonomic and motor. the botulinum toxin (botox®), which can exert a paralytic effect by binding to presynaptic cholinergic nerve terminals at the neuromuscular junction, is produced by the gram-positive, rod-shaped, spore-forming, anaerobic bacterium clostridium botulinum. it internalizes and inhibits the exocytosis of the neurotransmitter acetylcholine by decreasing the frequency of acetylcholine release

Eligibility criteria:
inclusion criteria: * age 18 and 65 years. * both sexes. * chronic migraine. chronic migraine, defined as headaches on ≥15 days per month for ≥3 months, of which ≥8 days meet criteria for migraine without aura or respond to migraine-specific treatment according to international classification of headache disorders-3 beta. exclusion criteria: * patients with medication over use headache. * bleeding disorders. * abnormal neurological examination. * history of allergy to local anesthetics or botox.